— Know what they know.
Not Investment Advice

DRNA NASDAQ

Dicerna Pharmaceuticals, Inc.
1W: +1.1% 1M: +0.6% 3M: +83.3% 1Y: +63.1% 3Y: +263.6% 5Y: +1153.1%
$38.22
Last traded 2021-12-27 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
$175M +25405.2% ▲
Capital Expenditures
$12M -85.0% ▼
5Y CAGR: +59.6%
Free Cash Flow
$163M +2420.2% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$24M -123.9% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2016FY2017FY2018FY2019FY2020
— Operating Activities —
Net Income-$60M-$60M-$89M-$120M-$113M
Depreciation & Amort.$840K$778K$774K$1M$2M
Stock-Based Comp.$9M$8M$8M$19M$39M
Change in Working Capital-$49M$64M$210M$3M$126M
Other Non-Cash Items$50M-$58M-$111M$97M$120M
Operating Cash Flow-$49M-$45M$18M-$692K$175M
— Investing Activities —
Capital Expenditures-$449K-$133K-$359K-$6M-$12M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$35M-$90M-$283M-$362M-$902M
Investment Sales$48M$70M$81M$418M$655M
Other Investing$0$372K$0$0$15K
Investing Cash Flow$13M-$19M-$203M$50M-$259M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased-$27K-$11K-$35K$0$0
Dividends Paid$0$0$0$0$0
Other Financing$534K$113M$170M$53M$59M
Financing Cash Flow$534K$113M$170M$53M$59M
Net Change in Cash-$35M$48M-$15M$102M-$24M
Cash End of Period$21M$69M$55M$157M$132M
Free Cash Flow-$49M-$45M$18M-$7M$163M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms